144 related articles for article (PubMed ID: 37272977)
41. Comparison of whole-body PET/CT and PET/MRI in breast cancer patients: lesion detection and quantitation of 18F-deoxyglucose uptake in lesions and in normal organ tissues.
Pace L; Nicolai E; Luongo A; Aiello M; Catalano OA; Soricelli A; Salvatore M
Eur J Radiol; 2014 Feb; 83(2):289-96. PubMed ID: 24331845
[TBL] [Abstract][Full Text] [Related]
42. Functional Characterization of Adrenocortical Masses in Nononcologic Patients Using
Ding J; Tong A; Zhang Y; Wen J; Zhang H; Hacker M; Huo L; Li X
J Nucl Med; 2022 Mar; 63(3):368-375. PubMed ID: 34301781
[TBL] [Abstract][Full Text] [Related]
43. CXCR4 expression in glioblastoma tissue and the potential for PET imaging and treatment with [
Jacobs SM; Wesseling P; de Keizer B; Tolboom N; Ververs FFT; Krijger GC; Westerman BA; Snijders TJ; Robe PA; van der Kolk AG
Eur J Nucl Med Mol Imaging; 2022 Jan; 49(2):481-491. PubMed ID: 33550492
[TBL] [Abstract][Full Text] [Related]
44. Molecular Imaging of Chemokine Receptor CXCR4 in Non-Small Cell Lung Cancer Using 68Ga-Pentixafor PET/CT: Comparison With 18F-FDG.
Derlin T; Jonigk D; Bauersachs J; Bengel FM
Clin Nucl Med; 2016 Apr; 41(4):e204-5. PubMed ID: 26756098
[TBL] [Abstract][Full Text] [Related]
45.
Bouter C; Meller B; Sahlmann CO; Staab W; Wester HJ; Kropf S; Meller J
J Nucl Med; 2018 Feb; 59(2):320-326. PubMed ID: 28729430
[TBL] [Abstract][Full Text] [Related]
46. Biodistribution and radiation dosimetry for the chemokine receptor CXCR4-targeting probe 68Ga-pentixafor.
Herrmann K; Lapa C; Wester HJ; Schottelius M; Schiepers C; Eberlein U; Bluemel C; Keller U; Knop S; Kropf S; Schirbel A; Buck AK; Lassmann M
J Nucl Med; 2015 Mar; 56(3):410-6. PubMed ID: 25698782
[TBL] [Abstract][Full Text] [Related]
47. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results.
Beiderwellen KJ; Poeppel TD; Hartung-Knemeyer V; Buchbender C; Kuehl H; Bockisch A; Lauenstein TC
Invest Radiol; 2013 May; 48(5):273-9. PubMed ID: 23493121
[TBL] [Abstract][Full Text] [Related]
48. Reduced splenic uptake on
Kraus S; Klassen P; Kircher M; Dierks A; Habringer S; Gäble A; Kortüm KM; Weinhold N; Ademaj-Kospiri V; Werner RA; Schirbel A; Buck AK; Herhaus P; Wester HJ; Rosenwald A; Weber WA; Einsele H; Keller U; Rasche L; Lapa C
Theranostics; 2022; 12(13):5986-5994. PubMed ID: 35966583
[TBL] [Abstract][Full Text] [Related]
49. Chemokine Receptor CXCR4-Targeted PET/CT With 68Ga-Pentixafor Shows Superiority to 18F-FDG in a Patient With Waldenström Macroglobulinemia.
Luo Y; Pan Q; Feng J; Cao X; Li F
Clin Nucl Med; 2018 Jul; 43(7):548-550. PubMed ID: 29742593
[TBL] [Abstract][Full Text] [Related]
50. 68 Ga-Pentixafor PET/CT for in-vivo mapping of CXCR4 receptors as potential radiotheranostic targets in soft tissue and bone sarcoma: preliminary results.
Jena SR; Watts A; Aggarwal P; Bachhal V; Kaur H; Dhingra K; Singh H; Bal A; Singh B
Nucl Med Commun; 2024 Mar; 45(3):229-235. PubMed ID: 38165171
[TBL] [Abstract][Full Text] [Related]
51. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in mantle cell lymphoma.
Albano D; Bosio G; Bianchetti N; Pagani C; Re A; Tucci A; Giubbini R; Bertagna F
Ann Nucl Med; 2019 Jul; 33(7):449-458. PubMed ID: 30929200
[TBL] [Abstract][Full Text] [Related]
52. Imaging the Cytokine Receptor CXCR4 in Atherosclerotic Plaques with the Radiotracer
Hyafil F; Pelisek J; Laitinen I; Schottelius M; Mohring M; Döring Y; van der Vorst EP; Kallmayer M; Steiger K; Poschenrieder A; Notni J; Fischer J; Baumgartner C; Rischpler C; Nekolla SG; Weber C; Eckstein HH; Wester HJ; Schwaiger M
J Nucl Med; 2017 Mar; 58(3):499-506. PubMed ID: 27789718
[No Abstract] [Full Text] [Related]
53. 18F-FDG, 11C-Methionine, and 68Ga-Pentixafor PET/CT in Patients with Smoldering Multiple Myeloma: Imaging Pattern and Clinical Features.
Zhou X; Dierks A; Kertels O; Kircher M; Schirbel A; Samnick S; Buck AK; Knorz S; Böckle D; Scheller L; Messerschmidt J; Barakat M; Kortüm KM; Rasche L; Einsele H; Lapa C
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32824832
[TBL] [Abstract][Full Text] [Related]
54. Detecting CXCR4 Expression in Meningioma on
Krebs S; Schwartz J; Grommes C; Young RJ; Schöder H; Mayerhoefer ME
J Nucl Med; 2023 Apr; 64(4):667-668. PubMed ID: 36357178
[No Abstract] [Full Text] [Related]
55. Standardized uptake values for [¹⁸F] FDG in normal organ tissues: comparison of whole-body PET/CT and PET/MRI.
Heusch P; Buchbender C; Beiderwellen K; Nensa F; Hartung-Knemeyer V; Lauenstein TC; Bockisch A; Forsting M; Antoch G; Heusner TA
Eur J Radiol; 2013 May; 82(5):870-6. PubMed ID: 23394765
[TBL] [Abstract][Full Text] [Related]
56. Synthesis, validation and quality controls of [68Ga]-DOTA-Pentixafor for PET imaging of chemokine receptor CXCR4 expression.
Sammartano A; Migliari S; Scarlattei M; Baldari G; Ruffini L
Acta Biomed; 2020 Jul; 91(4):e2020097. PubMed ID: 33525262
[TBL] [Abstract][Full Text] [Related]
57. CXCR4-Directed PET/CT in Patients with Newly Diagnosed Neuroendocrine Carcinomas.
Weich A; Werner RA; Buck AK; Hartrampf PE; Serfling SE; Scheurlen M; Wester HJ; Meining A; Kircher S; Higuchi T; Pomper MG; Rowe SP; Lapa C; Kircher M
Diagnostics (Basel); 2021 Mar; 11(4):. PubMed ID: 33805264
[TBL] [Abstract][Full Text] [Related]
58. Can Interim 18F-FDG PET or Diffusion-Weighted MRI Predict End-of-Treatment Outcome in FDG-Avid MALT Lymphoma After Rituximab-Based Therapy?: A Preliminary Study in 15 Patients.
Mayerhoefer ME; Karanikas G; Kletter K; Kiesewetter B; Weber M; Rausch I; Pones M; Simonitsch-Klupp I; Müllauer L; Dolak W; Lukas J; Raderer M
Clin Nucl Med; 2016 Nov; 41(11):837-843. PubMed ID: 27648705
[TBL] [Abstract][Full Text] [Related]
59. CXCR4-directed [
Chaman Baz AH; van de Wiel E; Groenewoud H; Arntz M; Gotthardt M; Deinum J; Langenhuijsen J
BMJ Open; 2022 Aug; 12(8):e060779. PubMed ID: 35998969
[TBL] [Abstract][Full Text] [Related]
60. CXCR4-Targeted PET Imaging of Central Nervous System B-Cell Lymphoma.
Herhaus P; Lipkova J; Lammer F; Yakushev I; Vag T; Slotta-Huspenina J; Habringer S; Lapa C; Pukrop T; Hellwig D; Wiestler B; Buck AK; Deckert M; Wester HJ; Bassermann F; Schwaiger M; Weber W; Menze B; Keller U
J Nucl Med; 2020 Dec; 61(12):1765-1771. PubMed ID: 32332145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
